Search research articles
Contact Us
Filters
Showing results (181-190 of 197) with videos related to
Page
of 20
Sort By:
Frontiers in Pharmacology
|
March 30, 2026
Xiao Chai Hu Tang-derived decoction (Tung-Yi Fang) suppresses triple negative breast cancer cells <i>in vitro</i> and <i>in vivo</i> via regulating EGFR/AXL-mediated signaling
Li-Lan Liao, Zhi-Hu Lin, Chia-Ching Liaw, et al.
American Journal of Cancer Research
|
April 6, 2019
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells
Ye Han, Mei-Kuang Chen, Hung-Ling Wang, et al.
American Journal of Cancer Research
|
April 13, 2017
A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma
Chun-Te Chen, Yi-Chun Chen, Yi Du, et al.
Cancer Research
|
August 26, 2024
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Mi Li, Amriti R Lulla, Yan Wang, et al.
Journal of Personalized Medicine
|
November 27, 2021
Genome-Wide Polygenic Risk Score for Predicting High Risk Glaucoma Individuals of Han Chinese Ancestry
Yu-Jer Hsiao, Hao-Kai Chuang, Sheng-Chu Chi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2017
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, et al.
American Journal of Cancer Research
|
March 21, 2020
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer
Yu-Yi Chu, Clinton Yam, Mei-Kuang Chen, et al.
Nature Communications
|
January 22, 2026
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction
Linjie Luo, Yan Wang, Tuyen Bui, et al.
Cancer Discovery
|
March 29, 2024
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Guang Lei, Chao Mao, Amber D Horbath, et al.
Cancer Research
|
June 28, 2014
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer
Yi-Hsin Hsu, Jun Yao, Li-Chuan Chan, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 197) with videos related to
Sort By:
Page
of 20
Frontiers in Pharmacology
|
March 30, 2026
Xiao Chai Hu Tang-derived decoction (Tung-Yi Fang) suppresses triple negative breast cancer cells <i>in vitro</i> and <i>in vivo</i> via regulating EGFR/AXL-mediated signaling
Li-Lan Liao, Zhi-Hu Lin, Chia-Ching Liaw, et al.
American Journal of Cancer Research
|
April 6, 2019
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells
Ye Han, Mei-Kuang Chen, Hung-Ling Wang, et al.
American Journal of Cancer Research
|
April 13, 2017
A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma
Chun-Te Chen, Yi-Chun Chen, Yi Du, et al.
Cancer Research
|
August 26, 2024
Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Mi Li, Amriti R Lulla, Yan Wang, et al.
Journal of Personalized Medicine
|
November 27, 2021
Genome-Wide Polygenic Risk Score for Predicting High Risk Glaucoma Individuals of Han Chinese Ancestry
Yu-Jer Hsiao, Hao-Kai Chuang, Sheng-Chu Chi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2017
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, et al.
American Journal of Cancer Research
|
March 21, 2020
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer
Yu-Yi Chu, Clinton Yam, Mei-Kuang Chen, et al.
Nature Communications
|
January 22, 2026
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction
Linjie Luo, Yan Wang, Tuyen Bui, et al.
Cancer Discovery
|
March 29, 2024
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Guang Lei, Chao Mao, Amber D Horbath, et al.
Cancer Research
|
June 28, 2014
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer
Yi-Hsin Hsu, Jun Yao, Li-Chuan Chan, et al.
Page
of 20